ABSTRACT. In this study, we examined the effects of four chemical reagents, 5 azacytidine (5azaC), all-trans-retinoic acid (ATRA), Phorbol 12-myristate 13-acetate (TPA) and trichostatin A (TSA), on an MCM-B2 canine mammary tumor cell line. Growth of the MCM-B2 cells was inhibited by addition of any of these four chemical reagents in a dose-dependent manner. TPA-treated cells became blast-celllike and had high expressions of cyclin D, cyclin B and PCNA. Both ATRA-treated and 5azaC-treated cells showed decreased expression of cell cycle related molecules and increased expressions of the mammary epithelial marker cytokeratin 18 and underwent morphological changes. ATRA-treated cells were converted from the originally spindle-shaped cells into cubic-shaped cells, and 5azaC-treated cells became fibroblast-like. In the TSA-treated cells, the cytoplasm was enlarged, increasing the cytoplasm/nucleus ratio, and the expressions of cell cycle-promoting molecules (cyclin D and PCNA), as well as cell cycle-inhibiting factors (p21 WAF1 and p27 kip1 ), were increased. These results demonstrated the growth-inhibiting, differentiation-inducing and antitumor effects of each of these four chemicals on the unique phenotype of canine mammary tumors.
, Yasuhiro ISHIKURA 1) , Takayuki NAKAGAWA 2) , Manabu MOCHIZUKI 2) , Ryohei NISHIMURA 2, 3) , Nobuo SASAKI 2) and Sumio SUGANO ABSTRACT . In this study, we examined the effects of four chemical reagents, 5 azacytidine (5azaC), all-trans-retinoic acid (ATRA), Phorbol 12-myristate 13-acetate (TPA) and trichostatin A (TSA), on an MCM-B2 canine mammary tumor cell line. Growth of the MCM-B2 cells was inhibited by addition of any of these four chemical reagents in a dose-dependent manner. TPA-treated cells became blast-celllike and had high expressions of cyclin D, cyclin B and PCNA. Both ATRA-treated and 5azaC-treated cells showed decreased expression of cell cycle related molecules and increased expressions of the mammary epithelial marker cytokeratin 18 and underwent morphological changes. ATRA-treated cells were converted from the originally spindle-shaped cells into cubic-shaped cells, and 5azaC-treated cells became fibroblast-like. In the TSA-treated cells, the cytoplasm was enlarged, increasing the cytoplasm/nucleus ratio, and the expressions of cell cycle-promoting molecules (cyclin D and PCNA), as well as cell cycle-inhibiting factors (p21 WAF1 and p27 kip1 ), were increased. These results demonstrated the growth-inhibiting, differentiation-inducing and antitumor effects of each of these four chemicals on the unique phenotype of canine mammary tumors. Canine mammary tumors are one of the most frequent neoplasms in dogs [4, 17, 19] , and since recurrence or metastasis is frequent, the tumors are defined as refractory diseases [13, 16] . Controlled clinical trials of treatments for this tumor are rare. Currently, surgical excision is the main treatment, while irradiation therapy and chemotherapy are also used [12] . Clinical trials evaluating the efficacy of irradiation therapy or chemotherapy, including anti-hormonal compounds, are rare despite the tumor's high occurrence rate [13, 16] .
About fifty percent of the tumors are malignant, and most of them are diagnosed as adenocarcinoma. Of the other half that are diagnosed as benign, most appear to be mixed tumors [1, 8] . These particular types of tumor formation are unique to canine mammary tumors, and it would be interesting to study this phenomenon from the perspective of cell biological behavior, in comparison to mammary tumors in humans and cats [17] .
Previous studies have reported induction of cell differentiation or tumor chemotherapy using various chemical reagents [7, 9, 11, 18, 23] , and 5azacytidine (5azaC) is known to have antitumor effects by inducing DNA hypomethylation. In DNA synthesis, genome-integrated 5azaC inhibits DNA methyltransferase (DNMT), resulting in genome-wide DNA hypomethylation, and consequently leads to antitumor effects and cell differentiation in hematopoietic tumors [10] . All-trans-retinoic acid (ATRA) induces leukemia cells to become differentiated to bind with retinoic receptor, and this mechanism is effective against acute promyelocytic leukemia (APL), specifically those expressing promyelocytic leukemia retinoid receptor alpha (PML-RAR) fusion gene [9] . Phorbol, 12-O-tetradecanoyl phorbol 13-acetate (TPA), which inhibits the protein phosphatase activities, has been used to induce cell differentiation in leukemia cells [23] , but also promotes cancerization [11] . Trichostatin A (TSA) was isolated from Streptomyces hygroscopicus [32] and acts as a histone deacetylase inhibitor (HDACI), which induces transcription. Previously, TSA treatments have induced cell differentiation in Friend leukemia cells [32] and osteosarcoma cells [25] , inhibited cell cycle promotion in fibroblast cells and induced apoptosis in osteosarcoma cells [22] .
Previous studies of canine mammary tumors have utilized MCM-B2 cells, an established cell line that combines multipotential differential ability [20] with tumorigenecity and is capable of anchorage-independent growth, and showed transplantation activity in athymic mice [21] . In our previous work on this cell line, we revealed the molecular antitumor mechanisms of sodium phenylacetate (NaPA) [28] and showed that NaPA works by inhibiting the Ras/mitogenactivated protein kinase (Ras/MAPK) signaling pathway to induce the reduction of c-Raf-1 protein, which transmits signals from activated Ras protein [29] . It is for this reason that we have chosen to use MCM-B2 cells because it is likely a suitable model for monitoring the antitumor activities and differentiation-inducing effects of various chemical reagents and anti-tumor drugs.
In this study, we examined the effects of cell proliferation and induction of cell differentiation on MCM-B2 canine mammary tumor cells using the four above-mentioned chemical reagents in order to contribute basic information for canine mammary tumor therapy.
MATERIALS AND METHODS

Cell line and chemical reagents:
The canine mammary tumor cell line, MCM-B2, was established from a benign mixed mammary tumor [20] . These cells were maintained in a one-to-one (v/v) mixture of Dulbecco's Modified Eagle's medium and Ham's nutrient mixture F-12 (DMEM/ F-12) (Sigma, St. Louis, MO, U.S.A.) supplemented with 10% fetal calf serum (FCS, CC. Laboratories, Cleveland, OH, U.S.A.), 100 mg/ml streptomycin and 100 IU/ml penicillin (Sigma), and were grown in an incubator in a 5% CO 2 atmosphere at 37C.
Four kinds of chemical reagent were used in this study. There were 5azaC (Sigma, St. Louis, MO, U.S.A.), ATRA (Sigma), TPA (Sigma) and TSA (CycLex Co., Ltd., Nagano, Japan).
Cell growth assay: Various concentrations of reagents were added to 2.0  10 2 cells grown in 96-well tissue culture plates (Nunc, Roskilde, Denmark). After 24 hr, the spent medium was replaced, and the cells were cultured in the absence or presence of chemical reagents at the doses of 100 mM, 10 M, 1 M, 100 nM, 10 nM, 1 nM, 100 pM, and 10 pM. After treatment for 3 days, the numbers of viable cells were measured using the CellTiter-Glo Luminescent Cell Viability Assay Kit (Promega, Madison, WI, U.S.A.). The signals were detected by a microtiter plate luminometer (Berthold Technologies, Wildbad, Germany) [15] .
Antibodies: The primary antibodies used for the Western blot evaluation were obtained from the following sources: cdk1/cdc2, cyclin B, cyclinD1, PCNA, p21 ), which were cultured in a 100-mm dish (Nunc, Roskilde, Demmark), were treated with 10 M and 50 M of 5azaC, 5 M and 10 M of ATRA, 25 nM and 50 nM of TPA and 0.5 nM and 1 nM of TSA. These concentrations of the chemical reagents were determined by referring to the values of the 50% inhibitory concentrations (IC 50 ) for the four reagents in a cell growth inhibition assay. After 3 days, treated or untreated cells were lysed in RIPA buffer (10 mM Tris-HCl, 1% NP40, 0.1% sodium deoxycholate, 0.1% SDS, 0.15 M NaCl, 1 mM EDTA, 10 g/ml aprotinin, 0.1 mM Na 2 MoO 4 , 2 mM Na 3 VO 4 , 1 mM PMSF, 10 mM NaF, 25 mM sodium -glycerophosphate, 10 mM sodium pyrophosphoric acid and 1 mM EGTA). The protein concentration was determined using BCA protein assay reagent (Pierce, Rockford, IL, U.S.A.). Cell lysates were boiled for 5 min in SDS sample buffer and then about 10 g per lane were resolved by SDS-PAGE and blotted onto a polyviniylidene difluoride membrane (PVDF; GE Healthcare, Buckinghamshire, UK). The blots were then incubated for 16 hr at 4C with TBST buffer containing 5% non-fat milk. They were then incubated with the appropriate first antibodies for 1 hr at RT, and subsequently incubated with horseradish phosphatase-conjugated antibodies against rabbit Ig (GE Healthcare) or mouse Ig (GE Healthcare) for 1 hr at RT. The signal was detected with an ECL Plus Western Blotting Detection System (GE Healthcare) [26] .
RESULTS
Effect of cell growth inhibition:
The antiproliferation effects on the MCM-B2 canine mammary tumor cell line are shown in Fig. 1 . Although growth of the cells was inhibited by addition of the reagents in a dose-dependent manner, at high concentrations, most cells were unable to survive. The cell concentrations in the dishes were maintained at a constant ratio while the TPA concentrations ranged from 10 nM to 10 pM. The fifty percent inhibitory concentrations (IC 50 ) of the four reagents were 24.90 M, 5.53 M, 33.01 nM and 0.70 nM for 5azaC, ATRA, TPA and TSA, respectively (Fig. 1) .
Cell morphological changes: The untreated cells were spindle-shaped ( Fig. 2A) , whereas the cells treated with 5azaC became fibroblast-like and sometimes grew in a storiform-like pattern (Fig. 2B) . The ATRA-treated cells grew in sheet-like layers and converted from being spindle shaped to cubic shaped (Fig. 2C) . The TPA-treated cells became small and blast-like (Fig. 2D) . In the TSA-treated MCM-B2 cells, the cytoplasm of the cells became enlarged, and the cytoplasmic/nuclear ratio was increased (Fig. 2E ).
Tumor and differentiation marker expression analysis:
The untreated MCM-B2 cells showed positive reactions with all antibodies (Fig. 3 lane 9) . In all treatments using the four chemical reagents, we monitored cell cycle-related molecules and found that cdk1/cdc2 was expressed at approximately equal levels. Compared with the untreated controls, the 5azaC-treated and ATRA-treated cells had decreased expressions of cyclin B, cyclin D, PCNA, p21 WAF1 and p27 kip1 ( Fig. 3 lanes 1-4) . In the TPA-treated cells, we found increased expression of cyclin B, distinct expression of cyclin D and PCNA and decreased expression of p21 WAF1 and p27 kip1 ( Fig. 3 lanes 5-6) . Finally, in the TSA-treated cells, we found high expression of cyclin D and increased expressions of p21 WAF1 and p27 kip1 ( Fig. 3 lanes 7-8) .
To evaluate the cell differentiation-inducing effects of the four chemical reagents, we observed the expressions of cytokeratin (CK) 14, CK18 and vimentin. CK18, a mammary epithelial cell marker, was expressed in the 5azaC-and ATRA-treated cells (Fig. 3 lanes 1-4) , and a weak signal was also detected in 25 nM of TPA-treated cells (Fig. 3 lane  5) . In contrast, the expression of CK14, a myoepithelial marker, decreased (Fig. 3 lanes 1-4) . In 50 nM TPA-treated cells, and in TSA-treated cells, we did observe increased expression of CK14 and vimentin, but did not detect CK18 expression (Fig. 3 lanes 5-8) . We also observed similar levels of expression of vimentin, a mesenchymal marker, in the treated cells.
DISCUSSION
In this report, we described the effects of 4 chemical reagents on cell growth inhibition and induced cell differentiation of MCM-B2 canine mammary tumor cells.
The untreated MCM-B2 cells showed positive results towards all antibodies used in this experiment, especially those with differentiation markers, such as CK14, CK18 and vimentin (Fig. 3) . These results led us to believe that the MCM-B2 cells may possess the ability to become multipotent [20] .
TPA is one of the most commonly used chemical reagents in the research of cell differentiation [23] and tumor promoting activity [11] in leukemia cells. In this study, the TPA-treated cells appeared to have irregular growth features, such as the loss of contact inhibition, and the cell growth rate was increased in the nanomolar concentration treatment. In protein expression analysis of the cells treated with 25 nM TPA, distinct expressions of cyclin D and p27 kip1 and weak expression of CK18 were observed. However, in the 50 nM TPA treatment, there were increased expressions of cyclin B and PCNA and no expression of CK18 (Fig. 3) . Since the expressions of the monitored cell molecules in the TPA-treated cells changed drastically over time and dosage, it would be interesting to evaluate the expressions and modifications of other cell cycle-related molecules, as well as to monitor, in more detail, the timedependent or dose-dependent changes of cell differentiation factors in TPA-treated cells.
Since TPA was proposed to have both tumor promoting activity and differentiation-inducing effects in leukemia cells [23] , differences of the treatment volumes might critically influence cell fates.
Treatment with ATRA has been studied for its ability to induce differentiation in tumor cells, both in experimental trials and in patients bearing leukemia [9] , with remarkable effects reported in tumor therapy experimental models [3, 27] . In this study, we showed drastic phenotype changes, down-regulation of cell cycle-related molecules and up-reg- ulation of mammary epithelial differentiation maker, CK18 (Fig. 3) . These results suggest that ATRA treatment might induce MCM-B2 cells to become epithelial cells. As we have previously demonstrated in some canine mammary tumor cell lines that express the ATRA ligand, retinoid receptor alpha (RAR), treatment with ATRA inhibits growth in 17 different canine tumor cell lines [15] . It would be interesting to evaluate the relationship between the degree of RAR expression, cell growth inhibitory activity and cell differentiation-inducing effects in various kinds of canine tumors. The accumulation of these data will contribute to the individualized treatment in tumor chemotherapy in the field of clinical veterinary. Experiments done using 5azaC and TSA have indicated that their antitumor activities involve modifying the genome-chromatin structure [30] . In the cell cycle-related protein expression analysis, the 5azaC-treated cells showed reduced expression in both cell cycle-promoting and inhibitory molecules. However, in the TSA-treated cells, we observed dominant expression of cyclin D and increased expressions of p21 WAF1 and p27 kip1 (Fig. 3) , suggesting that induction of cell cycle inhibitory factors might be caused by cell antiproliferative effects in TSA treatment. Although we showed increased CK18 expression in 5azaC-treated cells, no CK18 expression was observed in TSA-treated cells. Egger et al. proposed that DNA methylation keeps the chromatin structures more tightly packed, inhibiting transcription more than histone deacetylation, meaning that although a DNA methylation inhibitor alone can turn on transcription, it would be difficult to achieve the same result using only HDACI [5] . This model provides an explanation for our data, and indicates that a reduction in DNA methylation might be important in inducing cell differentiation in therapies targeted against canine mammary tumors.
In this study, we revealed some characteristics of MCM-B2 canine mammary tumor cells as well as their responses towards the four chemical reagents. Although no distinct effects were shown for TPA treatment, treatment with 5azaC, ATRA and TSA generated interesting data. In clinical application to canine mammary tumor therapy, ATRA treatment might be useful when RAR expression is detected, while 5azaC can be used as a DNMT inhibitor in clinical myelodysplastic syndrome (MDS) patients [31] . Although TSA itself has severe side effects, some HDACI reagents, such as suberoylanilide hydroxamic acid (SAHA) [2] , MS-275 [24] and FK228 [6] , are already being administered in clinical trials as treatments against several kinds of human tumor [14] . Yamashita et al. have even suggested combining DNMT with HDACI to produce a therapy with synergistic antitumor effects [32] . As of this study, however, we have only demonstrated the experimental antitumor effects. To adapt these chemical reagents for use in clinical canine mammary tumor therapy, we would need more experimental data and clinical trials, such as examinations of the synergetic effects of existing antitumor drugs, evaluations of side effects in each drug and pharmacokinetic analyses in dogs.
We hope that this study will create a foothold in the therapy against canine mammary tumors and studies of biological behaviors. 
